Pedic

Quick links to important sections

Pedic

Method of action: Bactericidal

Treatment option: Prostatitis, Urethritis, Cystitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pedic

Quick Facts

Property Description
Active Ingredient Pipemidic Acid (often as the trihydrate)
Primary Form Oral solid form (Tablet)
Pharmacological Class Quinolone Antibiotic (Synthetic Antibacterial Agent)
Common Use Fighting bacterial infections in the body
Origin Synthetic, Pyridopyrimidine derivative

What Type of Medicine is Pedic (Pipemidic Acid)?

Pedic is a clinically recognized synthetic antibacterial agent that belongs to the quinolone antibiotic group. Its therapeutic effect is derived solely from the active substance, Pipemidic Acid, which is chemically defined as a pyridopyrimidine derivative. Pipemidic Acid is grouped within "Other quinolones." The compound is entirely synthetic, a key characteristic distinguishing it from naturally derived antibiotics. The medication is an established older quinolone, utilized against specific bacterial populations, particularly Gram-negative organisms.


Composition and Available Forms of the Drug

The core of Pedic’s composition is its single active ingredient, Pipemidic Acid, which is prepared for systemic treatment via oral administration. The active compound is typically formulated as Pipemidic acid trihydrate, combined with pharmaceutical excipients that ensure stability and allow for proper absorption. This makes it a single-component product. The medication is commonly supplied in dosage forms suitable for the oral route, primarily the oral solid form (tablet), and occasionally an oral solution or suspension, facilitating convenient administration for the target adult patient group.


General Purpose of This Antibacterial Agent

The general purpose of this medication is to fight and eliminate bacterial infections throughout the body through a potent, bactericidal action. Pipemidic Acid functions by directly interfering with the ability of bacteria to thrive and multiply. It achieves this by blocking specific bacterial enzymes, namely DNA gyrase and Topoisomerase IV, which are vital for the uncoiling and repair of the bacteria’s genetic material. This mechanism involves the inhibition of bacterial nucleic acid synthesis, providing a defense against infections caused by susceptible pathogens.

What side effects are possible with Pedic?

Possible Side Effects and Safety Information for Pedic

Adverse reactions associated with Pedic are documented in regulatory sources and classified according to standard medical terminology based on the affected body system (System Organ Class) and frequency. The safety profile is established through clinical trials and post-market surveillance.

Key Safety Profile Elements

Common Adverse Reactions (Frequency ge 1/100 to < 1/10):

  • Gastrointestinal disturbances, such as nausea or diarrhea.
  • Nervous system effects, including headache or dizziness.
  • Skin and subcutaneous tissue disorders, which may present as a rash.

Serious and Clinically Significant Adverse Reactions:

Serious adverse reactions, as defined by health authorities (e.g., life-threatening events, hospitalizations, or persistent/significant disability), are rare but require prompt attention and are highlighted in the official labeling. These include severe hypersensitivity reactions and other specific organ toxicities. The official drug label will detail any known severe, unpredictable, or idiosyncratic reactions.

Population-Specific Safety Considerations:

Safety data for Pedic have been evaluated in pediatric populations, necessitating special attention to age-specific dosing and potential effects on growth and development, where applicable. The use of Pedic in certain younger age groups may be restricted or require specific monitoring protocols.

Safety Restrictions and Monitoring:

Pedic is contraindicated in individuals with a known hypersensitivity to the drug or its components. The official safety information may stipulate requirements for laboratory monitoring, such as blood cell counts or liver/renal function tests, to detect certain dose-dependent or time-dependent adverse effects. The drug’s use must be continuously weighed against potential risks, especially when used concurrently with other medicines.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Pedic

Overdose Scope

Element Official Regulatory Information (Pipemidic Acid)
Documented overdose presentations Central Nervous System (CNS) stimulation effects, including tremor, restlessness, confusion, and hallucinations or signs of a toxic psychosis.
Physiological systems affected (as stated in label) Central Nervous System and the Cardiovascular/Immune system (risk of severe systemic hypersensitivity).
Dose-related or exposure-related factors Clinical signs are related to the absorption of a massive dose of the quinolone agent.
Emergency-response statements Treatment is symptomatic and supportive. Emergency procedures may include airway management, epinephrine, oxygen, and intravenous steroids for severe reactions.

Overdose Classifications (High-Level)

Classification Official Regulatory Information (Pipemidic Acid)
Severity classification Defined by the risk of Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions and severe CNS events, potentially requiring resuscitation.
Overdose-context constraints Management is constrained by the fact that no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • A massive dose may lead to convulsions and increased intracranial pressure.
  • Overdose carries the risk of serious and occasionally fatal hypersensitivity that may result in cardiovascular collapse.
  • Immediate emergency treatment is required for severe manifestations such as seizures, loss of consciousness, or suspected anaphylaxis.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by highlighting the significant risk of CNS toxicity and life-threatening systemic events, mandating the immediate seeking of urgent medical attention upon suspicion of a massive dose. The official guidance emphasizes that management is strictly symptomatic and supportive due to the officially documented lack of a specific antidote.

Therapeutic Uses of Pedic

What Pedmark Pedic Treats: Main Uses and Benefits

Pedmark is a specialized supportive therapy used in situations involving certain distressing symptoms associated with intensive medical treatment, such as certain cancer regimens. This medicine is applied when appropriate in clinical settings that involve acute or unstable symptom patterns, particularly for children undergoing cancer treatment.

The core therapeutic use of Pedmark (sodium thiosulfate) may assist with managing the risk of ototoxicity—a type of hearing discomfort—in pediatric patients receiving cisplatin-based chemotherapy, specifically for localized, non-metastatic solid tumors. The medication addresses symptoms related to heightened physiological activity.

This agent contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability during this challenging treatment phase. This supportive management plays a role in managing the overall symptom load in children with localized, non-metastatic solid tumors who receive cisplatin-based chemotherapy. This may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Symptoms related to physiological strain

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Pedic (Pipemidic Acid)

Official regulatory documents define strict limitations for the use of Pipemidic Acid, primarily allowing it for adults with normal organ function, subject to other restrictions.

Eligibility Exclusions

Pipemidic Acid is officially contraindicated and must not be used in the following populations:

  • Infants, Children, and Adolescents: Contraindicated in all growing individuals due to the risk of articular cartilage damage.
  • Pregnancy and Lactation: Contraindicated for use during pregnancy and while breastfeeding.
  • Hypersensitivity: Patients with known allergies to pipemidic acid, any other quinolone antibacterial, or product excipients.
  • Tendinopathy History: Individuals with a history of tendon disorders related to previous quinolone use.

Conditional Use and Regulatory Status

Use requires conditional consideration in older adults due to an elevated risk of tendon damage. Patients with severe renal or hepatic impairment also require conditional use, potentially involving careful management.

Additionally, the marketing authorization for medicines containing Pipemidic Acid has been suspended throughout the European Union (EU) by the EMA, reflecting significant regulatory restrictions on its availability and use.

What should I know about interactions with other medicines?

Pedic Interactions with other medicines and products

The drug Pexidartinib (a common spelling for Pedic in medical contexts, brand name Turalio) has a high potential for clinically significant interactions with other medicinal products, herbal supplements, and specific foods. These interactions are primarily pharmacokinetic in nature, involving the drug's metabolism and absorption.


Key Interaction Mechanisms

  • Enzyme Induction and Inhibition: Pexidartinib acts as an inducer of the CYP3A4 enzyme, which can significantly decrease the concentrations and therapeutic effect of other drugs metabolized by this pathway (known as CYP3A4 substrates).
  • CYP3A4 Inhibitors and Inducers: Co-administration with strong CYP3A4 inhibitors (e.g., certain antifungals like ketoconazole or antivirals like atazanavir) can increase Pexidartinib levels, raising the risk of adverse effects. Conversely, strong CYP3A4 inducers (e.g., rifampin, St. John's wort, certain anticonvulsants) can decrease Pexidartinib levels, reducing its effectiveness. Dose adjustments are typically required when these combinations are unavoidable.
  • Gastric pH Modifiers: The absorption of Pexidartinib is affected by gastric acidity. Proton pump inhibitors (PPIs) are generally contraindicated. H2-receptor blockers require a time-separated administration (e.g., Pexidartinib two hours after the H2-blocker, or the H2-blocker 10 hours before Pexidartinib). Antacids must also be separated by at least two hours.

Important Co-administration Restrictions

Interacting Product Category Interaction Relevance Condition/Instruction
Hepatotoxic Agents (Products known to cause liver damage) Major Interaction Co-administration is generally avoided due to additive risk of hepatotoxicity.
Hormonal Contraceptives (Estrogen/Progestin) Clinically Significant Pexidartinib may decrease contraceptive effectiveness; alternate/additional non-hormonal birth control is required.
Grapefruit/Grapefruit Juice Major Interaction Strictly contraindicated; may increase Pexidartinib concentration and toxicity.
High-Fat Meals Impact on Safety Avoid; taking the drug with a high-fat meal can increase the risk of side effects.

Mechanism of Action

The mechanism of action centers on the inhibition of central nervous system (CNS) cyclooxygenase (COX) enzymes, primarily the COX-2 isoform. The agent acts as an inhibitor of the peroxidase active site on the COX enzyme, preferentially in environments of low peroxide concentration characteristic of the CNS, distinguishing its activity from peripheral nonsteroidal agents. This molecular interaction results in the decreased synthesis of prostaglandins, specifically prostaglandin E2 ( PGE2), within the hypothalamus. The reduction of PGE2 concentration facilitates the modulation of the hypothalamic thermoregulatory set-point, leading to a downstream physiological consequence of peripheral vasodilation and increased heat dissipation via non-sweating diaphoresis. Simultaneously, the inhibition of prostaglandin synthesis in the CNS contributes to a centrally mediated increase in the perception threshold for nociceptive stimuli, modulating afferent pain signaling.

Dosage and Administration Information

How to Use Pedic (Pipemidic Acid)

Pipemidic Acid is an antibacterial agent whose administration is characterized by usage principles observed in clinical and statistical records. The standard method for systemic delivery involves the oral route of administration, consistent with its formulation as an oral solid form, such as a tablet or capsule. The medicine is generally well-absorbed after oral intake, which guides its use in the absence of specific mandatory meal-timing restrictions in core documentation.

The basis for daily consumption is defined by the Defined Daily Dose (DDD), a statistical reference unit, for Pipemidic Acid.

Parameter Administration Parameters
Route of administration Oral (O) for systemic treatment.
Reference Dosing Basis The Defined Daily Dose (DDD) is 0.8 grams per day.
Frequency Pattern Daily, generally administered in divided doses to align with the 0.8 g reference dose.
Course Duration Used for a short-term, defined course typical of acute bacterial regimens.

Procedural Structure

Usage is structured as a standardized oral regimen where the daily intake is anchored to the 0.8 gram reference dose. This establishes the fundamental procedural pattern for its use. While the medication was historically used for a short-term, acute course, available documentation does not provide detailed, prescriptive instructions for managing a missed dose or specific dose adjustments for groups like older adults or those with organ impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pedic

Research Context: Studies Involving Children

Research exploring how symptoms change over time for conditions characterized by fluctuating or episodic manifestations was studied for in the population of children and adolescents. These studies are often used in research exploring the unique physiological and developmental factors that apply to younger individuals. Therefore, research must also examine evidence derived from settings with varying symptom burdens. Research often focuses on outcomes reflecting daily functioning or activity level to understand the real-world scope of the condition. Studies focus on episodes where symptoms become more noticeable, examining symptom intensity or variability to contribute to the broader evidence landscape. This research aims to provide insight into short-term changes and how symptoms evolved in the observed populations, helping to contextualize how patients reported their experience.


Focus Area: Conditions Characterized by Visual Outcomes

Research has examined specific conditions marked by functional limitations where visual outcomes related to systemic or functional imbalance are monitored. For certain visual conditions like amblyopia, or "lazy eye," multiple approaches were evaluated in observational settings and trials. Studies explored whether approaches such as patching the eye or using medication may influence vision over defined time intervals. Findings describe patterns observed in the studies, suggesting that for moderate cases, treatment administered for shorter daily periods appears to be associated with outcomes observed during longer periods in studies examining patient-reported experiences. Evidence suggests that research exploring these forms of observation and evaluation at a younger age may describe different patterns observed in the studies compared with research in older children.


Limitations and Ongoing Research

While research provides context, the evidence is limited in several areas related to the Pedic population. Research limitation frames indicate that results apply only to the populations studied, and comparative evidence is lacking for certain treatment approaches. Data are still emerging regarding observed patterns, and certainty remains low for certain variations in treatment regimens. Follow-up durations were limited in some studies, meaning that the long-term effects of many interventions are not fully established. Research provides context but not individual predictions, and the overall evidence quality varies across studies.

Key Studies & References

  1. A Randomized Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia (ATS02A)

Frequently Asked Questions (FAQ)

Common questions about Pedic (FAQ)


Q: How quickly should someone expect Pedic to start working?

Regulatory documents describe the pharmacokinetics of Pedic, which is how the drug moves through the body. Information indicates that the drug typically reaches its highest concentration in the bloodstream within one to three hours after being taken. This concentration information is part of understanding the drug's properties after administration.


Q: How long does one dose of Pedic typically last in the body?

The official pharmacokinetic data for Pedic estimates the elimination half-life, which is the time it takes for half of the medicine to be cleared from the system. This half-life is typically cited as ranging from two to four hours. This helps understand the drug’s persistence in the body.


Q: What are the official recommendations for managing a missed dose of Pedic?

The instructions for use provided in regulatory documents generally describe a procedure where, if a dose is missed, it is advised to skip that dose entirely. The recommended procedure is to then resume the regular dosing schedule with the next scheduled dose, without trying to take extra medication to make up for the one that was missed.


Q: Does Pedic cause changes in appetite or weight?

Official reports on side effects classify changes in appetite as a possible effect. Specifically, regulatory documents report anorexia, which is a loss of appetite, as an occasional adverse reaction to the medicine. Significant weight changes are not typically listed among the commonly reported effects.


Q: Is Pedic known to cause mood changes or depression?

Regulatory labeling addresses possible effects on the nervous and psychiatric systems. Official reports list psychiatric events, including anxiety and confusion, as potential side effects. Depressive reactions are also noted in documentation as a possible, though rarer, adverse event.


Q: What kind of research evidence supports the use of Pedic?

Studies and official information indicate that Pipemidic Acid is utilized for clearing susceptible bacterial strains in the approved patient population and indications. The evidence supports the drug's approved use within the designated patient population and for the specific infections listed on the label.


Q: What medical tests might be recommended while taking Pedic?

Official safety information includes a note that patients undergoing longer-term therapy with Pedic may be subject to periodic laboratory monitoring. This monitoring is typically used to check blood cell counts and assess liver and kidney function.


Q: Can Pedic be used for other issues besides its main approved use?

Regulatory documents strictly list the specific infections and patient groups for which the drug has official approval and is indicated for use. The use of Pedic is limited to those specific indications supported by official authorization.


Q: Is it okay to take Pedic every day for a long period of time?

The approved course of treatment for Pedic is generally defined as short-term. Official usage guidelines align with regimens typical for acute bacterial infections, and the duration is specified in the treatment plan.


Q: Does Pedic make you feel sleepy or drowsy?

Adverse effect reports indicate that effects on the nervous system are possible. Drowsiness (somnolence) and dizziness are listed in official product information among the reported, less common adverse effects.


Q: Can Pedic cause problems with sleep or insomnia?

Insomnia, meaning difficulty sleeping, is listed within the regulatory documentation as a possible adverse reaction. It is not generally listed as one of the most frequent side effects.


Q: Is it safe to take Pedic if I also take a vitamin or supplement?

Official drug interaction warnings advise caution with certain herbal products. Specifically, official drug interaction warnings describe that co-administration with the herbal product St. John’s wort is advised against, as it has the potential to reduce the drug's effectiveness.


Q: What types of over-the-counter pain relievers can interact with Pedic?

Regulatory texts mention an interaction concern with certain nonsteroidal anti-inflammatory drugs (NSAIDs). Co-administration with some NSAIDs may carry an increased risk of effects on the central nervous system, such as excitation or seizures.


Q: Does consuming caffeine affect how Pedic works?

Official interaction information notes that quinolone antibiotics, the class of medicine to which Pedic belongs, may slow the way the body processes caffeine. This interaction could result in higher-than-normal caffeine concentrations and potentially increased related effects.


Q: Can older adults (seniors) use Pedic safely?

Official safety information confirms that use in older adults requires caution and conditional consideration. This is due to an elevated risk of specific adverse reactions in this age group, such as certain types of tendon damage.


Q: Is Pedic a controlled substance or addictive?

According to the official regulatory classification, Pedic is a pharmaceutical drug that is not classified as a controlled substance. It is not listed under the federal Controlled Substances Act (CSA).


Q: Is it normal to feel a mild headache when first starting Pedic?

Regulatory documentation lists headache as a common adverse reaction associated with the use of this medicine. However, official labels do not generally provide information or address the specific timing of the onset of side effects, such as when starting treatment.


Q: Does Pedic interact with common medicines used for high blood pressure?

The drug is described in regulatory documents as an inducer of the CYP3A4 enzyme. This means it has the potential to decrease the concentration of many other drugs metabolized by this enzyme, a group which includes certain common cardiovascular agents.


Q: How long after stopping Pedic does it take for the drug to clear the system?

Regulatory pharmacokinetic data indicates that the drug is cleared from the body primarily through the kidneys. The rate at which the drug is cleared can be estimated using the elimination half-life data reported in official product information.


Q: Is it okay to stop taking Pedic suddenly?

Official guidelines describe that the full course of treatment is intended to be completed. This approach is described as essential to help prevent the development of resistant bacteria, even if symptoms begin to improve.


Q: What is the risk of an allergic reaction to Pedic?

The most serious allergic reaction risk is addressed by contraindication. Official documents state that the medicine is strictly contraindicated for use in individuals who have a known hypersensitivity to the drug or any other quinolone antibiotic.


Q: Is there a maximum amount of time a person is supposed to use Pedic?

Official guidelines define the drug’s use as a short-term, defined course. The specific duration is determined by the healthcare provider and is typical for the treatment of acute bacterial regimens.


Q: Are there different strengths or dosages of Pedic available?

Regulatory documents specify the pharmaceutical forms and strengths available. The formulations typically include tablets in a specific single strength, such as 400 mg, which is aligned with the drug's reference daily dose.


Q: What should a person do if they notice a potential interaction between Pedic and another drug?

Official patient information advises that immediate contact with a healthcare provider is recommended if signs of a serious drug interaction or adverse effect are suspected. This step is cited as the required action when a problem is noticed.


Q: Are there different formulations of Pedic (e.g., tablet, liquid, extended-release)?

Regulatory documentation confirms the available dosage forms. The medication is commonly supplied as an oral solid form (tablet) and, in some cases, an oral solution or suspension is also available.


Q: Is Pedic commonly used worldwide or only in certain regions?

Official regulatory information provides status in various regions. For example, the marketing authorization for medicines containing Pipemidic Acid has been confirmed as suspended throughout the European Union (EU).


Q: Are there specific patient groups where the side effects of Pedic are more common?

Regulatory documentation details use in specific populations. Older adults and pediatric patients are identified as groups that may require special attention to potential adverse effects.


Q: What is the mechanism by which Pedic relieves symptoms?

Pedic is an antibacterial agent, and its function is to fight infection. The mechanism involves blocking essential bacterial enzymes, namely DNA gyrase and Topoisomerase IV, which prevents the growth of the infecting organism and resolves the infection.


Q: Does Pedic have any impact on a person's ability to drive or operate machinery?

Regulatory texts explicitly caution regarding potential side effects on the central nervous system. Due to the possibility of adverse effects like dizziness or drowsiness, product information indicates that caution should be exercised when driving or operating machinery.

How should Pedic be stored and disposed of?

How to Store and Dispose of Pedic?

Storing Pedic correctly ensures the medicine maintains its quality, strength, and purity throughout its shelf life, as defined by regulatory standards. The product must be stored according to the labeled temperature and environmental controls, typically requiring storage at controlled room temperature or the specified refrigerated range, and must be protected from excessive moisture and light. Always keep the medicine in its original container with the closure tightly sealed.

For security and protection, Pedic must be stored out of sight and out of reach of children to prevent accidental ingestion. When disposing of unused, unwanted, or expired medication, patients should follow official disposal instructions. The preferred method is often returning the drug to a designated drug take-back program or a medication disposal location. If these are unavailable, it must be disposed of securely in the household trash as directed by official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pedic found in:

A-Z Index: